Targeting HMGB2 Acts As Dual Immunomodulator by Bolstering CD8+ T Cell Function and Inhibiting Tumor Growth in Hepatocellular Carcinoma

The authors analyzed human and murine single-cell RNA sequencing data and identified the underlying mechanisms of high-mobility group box 2 (HMGB2) promoting HCC progression through dual action on effector T cells and cancer cells, respectively.